Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kamonwan, Kongrak"'
Autor:
Anthony M. Joshua, Louise Emmett, Christopher Rofe, Jesse A Ende, Andrew Nguyen, Arnavaz Danesh, Edmond M. Kwan, Lyn Chan, Andrew O. Yam, Shikha Sharma, Megan Crumbaker, Joanne Keane, Sarennya Pathmanandavel, Kamonwan Kongrak, Bao Ho, Peter Eu, Trevor J. Pugh, Arun Azad
Publikováno v:
European Urology Oncology. 4:963-970
Background Trials of lutetium prostate specific membrane antigen (PSMA) in men with metastatic castration-resistant prostate cancer (mCRPC) have demonstrated good safety and efficacy, but combination strategies may improve outcomes. Idronoxil is a sy
Autor:
Megan, Crumbaker, Sarennya, Pathmanandavel, Andrew O, Yam, Andrew, Nguyen, Bao, Ho, Lyn, Chan, Jesse A, Ende, Christopher, Rofe, Kamonwan, Kongrak, Edmond M, Kwan, Arun A, Azad, Shikha, Sharma, Trevor J, Pugh, Arnavaz, Danesh, Joanne, Keane, Peter, Eu, Anthony M, Joshua, Louise, Emmett
Publikováno v:
European urology oncology. 4(6)
Trials of lutetium prostate specific membrane antigen (PSMA) in men with metastatic castration-resistant prostate cancer (mCRPC) have demonstrated good safety and efficacy, but combination strategies may improve outcomes. Idronoxil is a synthetic fla
Autor:
Megan Crumbaker, Louise Emmett, Andrew O. Yam, Lalith Ratnayake, Wai Ling Chan, Andrew Nguyen, Edmond M. Kwan, Anthony M. Joshua, Arun Azad, Peter Eu, Shikha Sharma, Christopher Rofe, Bao Ho, Kamonwan Kongrak, Adam Hickey, Sarennya Pathmanandavel
Publikováno v:
Journal of Clinical Oncology. 39:103-103
103 Background: 177LuPSMA – 617 is a promising therapy for metastatic castrate-resistant prostate cancer (mCRPC). However, treatment resistance occurs frequently and synergistic combination therapy may improve outcomes. We combined 177LuPSMA – 61
Autor:
Sarennya Pathmanandavel, Peter Eu, Wai Ling Chan, Louise Emmett, Christopher Rofe, Andrew O. Yam, Megan Crumbaker, Karen Fullard, John Violet, Lalith Ratnayake, Kamonwan Kongrak, Adam Hickey, Anthony M. Joshua, Bao Ho, Shikha Sharma, Arun Azad, Andrew Nguyen, Joanne Keane
Publikováno v:
Journal of Clinical Oncology. 38:5557-5557
5557 Background: There is no established standard of care post cabazitaxel in men with mCRPC. Ongoing trials in 177LuPSMA-617 have demonstrated good efficacy and safety, but synergistic combinations may further improve treatment responses. Idronoxil